• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Hennigan Michael J

    6/3/25 5:04:45 PM ET
    $CI
    Medical Specialities
    Health Care
    Get the next $CI alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Hennigan Michael J

    (Last) (First) (Middle)
    900 COTTAGE GROVE ROAD

    (Street)
    BLOOMFIELD CT 06002

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    06/02/2025
    3. Issuer Name and Ticker or Trading Symbol
    Cigna Group [ CI ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit List: EX-24 Power of Attorney poahennigan.txt
    No securities are beneficially owned.
    Tyler Gratton, attorney-in-fact 06/02/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CI

    DatePrice TargetRatingAnalyst
    2/6/2025$323.00Outperform → Mkt Perform
    Bernstein
    6/26/2024$400.00Overweight
    Piper Sandler
    5/30/2024$388.00Outperform
    Robert W. Baird
    3/6/2024$393.00Overweight
    Barclays
    2/5/2024$334.00 → $372.00Neutral → Overweight
    Cantor Fitzgerald
    2/5/2024$327.00 → $354.00Sector Perform → Outperform
    RBC Capital Mkts
    2/1/2024$355.00 → $370.00Hold → Buy
    Deutsche Bank
    1/4/2024$330.00 → $372.00Mkt Perform → Outperform
    Bernstein
    More analyst ratings

    $CI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • The Cigna Group downgraded by Bernstein with a new price target

      Bernstein downgraded The Cigna Group from Outperform to Mkt Perform and set a new price target of $323.00

      2/6/25 7:05:01 AM ET
      $CI
      Medical Specialities
      Health Care
    • Piper Sandler initiated coverage on The Cigna Group with a new price target

      Piper Sandler initiated coverage of The Cigna Group with a rating of Overweight and set a new price target of $400.00

      6/26/24 7:28:18 AM ET
      $CI
      Medical Specialities
      Health Care
    • Robert W. Baird initiated coverage on The Cigna Group with a new price target

      Robert W. Baird initiated coverage of The Cigna Group with a rating of Outperform and set a new price target of $388.00

      5/30/24 7:35:19 AM ET
      $CI
      Medical Specialities
      Health Care